Over 280 million Covid vaccine doses to be produced in October: Mandaviya

Mandaviya said that nearly 73 percent of the eligible population has received a single dose of vaccine

vaccine
A health worker administers a dose of COVID-19 vaccine to a beneficiary, at a district hospital in Noida (Photo: PTI)
Press Trust of India New Delhi
2 min read Last Updated : Oct 13 2021 | 7:50 PM IST

Noting that India's COVID-19 vaccination will cross the landmark of 100 crore vaccine doses in a few days, Union Health Minister Mansukh Mandaviya said on Wednesday that the country will produce over 28 crore doses in October as it continues to ramp up its supply.

Speaking to reporters, Mandaviya said that nearly 73 percent of the eligible population has received a single dose of vaccine and around 29 percent both doses.

States have now over eight crore doses with them, he said.

Of the 28 crore doses to be available this month, up from more than 22 crore in September, nearly 22 crore will be Covishield and six crore will be Covaxin. Also, nearly 60 lakh DNA jabs will be produced, he said.

With around 97 crore vaccine doses administered so far, the numbers are expected to reach the 100 crore milestone next week, likely on October 19 or 20, he said.

Official sources said that as of now the health ministry has no plans to push booster doses as expert opinion on the matter is yet to crystallise.

They also expressed satisfaction at the overall vaccination programme, saying hardly any state is now complaining about lack of vaccines.

Asked about the political blame game between the Delhi BJP and the Aam Aadmi Party government in the national capital over restraint on the Chhath puja due to the pandemic, they noted that all states have SOPs in place about the observation of festivities and no politics should be done over this.

The Delhi government has written a letter to Mandaviya in this regard after the local BJP unit targeted the Arvind Kejriwal-led dispensation over it.

Asked whether the Union government is considering resumption of vaccine exports, official sources said it will be looked at only after the domestic requirement is met.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Oct 13 2021 | 7:48 PM IST

Next Story